Flukonazol-Darnitsa capsules are appointed at the following indications:

Adult:

• Treatment: cryptococcal meningitis; coccidioidosis; invasive candidiases; candidiasis of mucous membranes, including candidiasis of a stomatopharynx, a gullet, a kandiduriya, chronic candidiasis of skin and mucous membranes; chronic atrophic candidiasis (the candidiasis caused by use of dentures) at inefficiency of local dental hygienic means; vaginal candidiasis, sharp or recurrent when local therapy is not appropriate; a candidosis balanitis when local therapy is not appropriate; including mycosis of feet, smooth skin, a pakhovy dermatomycosis, multi-colored deprive dermatomycoses, candidosis infections of skin when system therapy is not appropriate; a dermatophyte onychomycosis when use of other medicines is not appropriate.
• Prevention: a recurrence of cryptococcal meningitis at patients with high risk of its development; a recurrence of candidiasis of a stomatopharynx or a gullet at patients with HIV with high risk of its development; decrease in frequency of a recurrence of vaginal candidiasis (4 or more cases a year); prevention of candidosis infections at patients with a long neutropenia (for example, patients with malignant diseases of blood which receive chemotherapy, or patients at transplantation of haematopoietic stem cells).

Children:

• Treatment: cryptococcal meningitis; candidiases of mucous membranes; invasive candidiases.
• Prevention of candidosis infections at patients with reduced immunity.
• Medicine can be applied as maintenance therapy to prevention of a recurrence of cryptococcal meningitis at children with high risk of its development.
Therapy by medicine can be begun with
• before obtaining results of cultural and other laboratory researches; after obtaining results the antibacterial treatment should be corrected as appropriate.

Structure

Active ingredient: fluconazole;

1 capsule supports a flukonazol of 50 mg, 100 mg or 150 mg;

Excipients: potato starch, lactose monohydrate, silicon dioxide colloidal waterless, sodium lauryl sulfate, magnesium stearate, gelatin, titan dioxide (E 171).

Contraindication

• Hypersensitivity to a flukonazol, other azolny connections or to other components of medicine;
• Simultaneous application of a flukonazol and terfenadin to the patients applying flukonazol repeatedly in doses of 400 mg/days and above (by results of a research of interaction of repeated application);
• Simultaneous application of a flukonazol and other medicines extending an interval of QT and which are metabolized by means of CYP3A4 enzyme (for example, a tsizaprida, an astemizola, Pimozidum, quinidine and erythromycin).

Medicine to accept

inside. To swallow capsules entirely irrespective of meal.

Drug dose depends on a look and weight of a fungal infection. For the majority of cases of vaginal candidiasis of rather single use of medicine. In need of repeated use of medicine the treatment of infections should be continued before disappearance of clinical and laboratory manifestations of activity of a fungal infection. The insufficient duration of treatment can lead to resuming of active infectious process.

to

Feature of application

Pregnant

Data obtained at single or repeated application of a flukonazol in usual doses (<200 mg/days) to several hundred pregnant women during the I trimester of pregnancy, did not show undesirable effects on a fruit. It was reported about numerous congenital pathologies at newborns (including a brachycephaly, an auricle dysplasia, excessive increase in a front fontanel, a hip curvature, a humero-ulnar synostosis), at application to pregnant women of high doses of a flukonazol (400–800 mg/days) within at least 3 months for treatment of a coccidioidosis. Communication between application of a flukonazol and these cases is not defined.

Research on animals reproductive toxicity.

should not apply usual doses of a flukonazol and short-term courses of treatment flukonazoly during pregnancy, except for emergency.

should not apply high doses of a flukonazol and/or long courses of treatment flukonazoly during pregnancy, except for treatment of infections which threaten life.

Medicine in the form of capsules this category of patients can apply

when children are capable to swallow safely the capsule that is usually possible aged from 5 years.

Drivers

Researches of influence of a flukonazol on ability to steer motor transport or to work with other mechanisms. Patsiyentov it is necessary to inform on a possibility of development of dizziness or spasms at use of medicine. At development of such symptoms it is not recommended to steer motor transport or other mechanisms.

Overdose

It was reported about overdose of a flukonazol and development of hallucinations and paranoid behavior.

Treatment: symptomatic maintenance therapy and if necessary – gastric lavage. Flukonazol is substantially excreted with urine therefore the artificial diuresis can accelerate medicine removal. The session of a hemodialysis lasting 3 hours reduces the level of a flukonazol in blood plasma approximately by 50%.

Side effects

Most often (> 1/10) it was reported about such side reactions: headache, abdominal cavity pain, diarrhea, nausea, vomiting, rash, increase in level of alaninaminotranspherase (ALT), aspartate aminotransferase (nuclear heating plant) and alkaline phosphatase of blood.

Interaction

Tsizaprid, astemizol, Pimozidum, quinidine, erythromycin: simultaneous use of the above-stated medicines and a flukonazol can lead to lengthening of an interval of QT, Bouveret's ventricular disease like "pirouette" and, as a result, by sudden death. Use of a combination of these medicines is contraindicated.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 3 years.